5,489 Shares in Regeneron Pharmaceuticals, Inc. $REGN Acquired by Te Ahumairangi Investment Management Ltd

Te Ahumairangi Investment Management Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 5,489 shares of the biopharmaceutical company’s stock, valued at approximately $3,423,000.

Several other institutional investors and hedge funds have also modified their holdings of the business. BlackRock Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $5,682,636,000. Norges Bank bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $1,012,296,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares in the last quarter. Nuveen LLC lifted its holdings in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after buying an additional 835,240 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at $472,950,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have commented on the stock. Benchmark raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Citigroup boosted their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Wells Fargo & Company boosted their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the company an “equal weight” rating in a report on Friday, July 31st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $801.70.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $834.04 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $847.00. The stock has a market capitalization of $85.87 billion, a price-to-earnings ratio of 20.61, a PEG ratio of 1.42 and a beta of 0.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The business has a 50-day moving average of $697.09 and a 200-day moving average of $716.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The firm had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue was up 16.7% compared to the same quarter last year. During the same period last year, the company earned $12.81 earnings per share. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director directly owned 603 shares of the company’s stock, valued at approximately $482,400. The trade was a 39.88% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,400 shares of company stock worth $1,090,030 over the last three months. Insiders own 6.97% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva (FOP). Approval was supported by the Phase 3 OPTIMA trial, which showed a 90% or greater reduction in new lesions at 56 weeks. As the first approved treatment demonstrating this benefit in FOP, Pasatru could expand Regeneron’s rare-disease portfolio and create a new revenue stream. Regeneron to challenge Ipsen as FDA clears bone disease drug
• Positive Sentiment: Regeneron is also pursuing growth in obesity treatment. An update on its Phase 2 olatorepatide study has drawn investor attention because the program could give the company exposure to the large and rapidly expanding obesity-drug market, although clinical and commercial risks remain. Regeneron’s Olatorepatide Trial Signals a Bid for Obesity Market Upside
• Neutral Sentiment: Multiple investor-law-firm notices announced a securities class action and a September 14, 2026 lead-plaintiff deadline. The claims relate to alleged disclosures about the Phase 3 Fianlimab-Libtayo melanoma trial; the notices themselves do not represent a new regulatory or operating development. Regeneron Investors Class Action Notice
• Negative Sentiment: The underlying litigation alleges that Regeneron misled investors about the viability and prospects of the Fianlimab-Libtayo trial, whose disappointing results reportedly caused a sharp share-price decline and an approximately $11 billion reduction in market value. Continued lawsuit announcements add reputational, legal-cost and potential financial-liability risks. Pomerantz Regeneron Investor Alert

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.